(rel) -PRT062607

• Description:

  (rel) -PRT062607 ((rel) -P505-15) is the relative configuration of PRT062607 (HY-15322) . PRT062607 is a highly selective inhibitor of Syk kinase, with an IC50 value of 1-2 nM, and is more than 80 times less potent against Fgr, Lyn, FAK, Pyk2, and Zap70.

• Product Name Alternative:

  (rel) -P505-15; (rel) -PRT-2607; (rel) -BIIB-057

• UNSPSC:

  12352100

• Target:

  Drug Isomer; Syk

• Related Pathways:

  Others; Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  NC (C (C (NC1=CC (N2N=CC=N2) =CC=C1) =N3) =CN=C3N[C@H]4[C@H] (CCCC4) N) =O

• Molecular Formula:

  C19H23N9O

• Molecular Weight:

  393.45

• References & Citations:

  [1]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340 (2) :350-9.|[2]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344 (2) :378-87.|[3]Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul;26 (7) :1576-83.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1194954-52-3